There are a lot of options for Aussie investors to choose from on the local share market.

But which ones could be buys today? Let's see what analysts are saying about these popular options, courtesy of The Bull . Here's what you need to know:

The team at Red Leaf Securities thinks that this biotech giant has been oversold and have named it as an ASX share to buy this week.

It highlights CSL's buyback, transformational restructuring, and demand tailwinds as reasons to be positive. Red Leaf said:

This biotechnology company is massively oversold, in our view. CSL offers a rare chance to buy a global plasma therapy powerhouse at a discount. Its $1.5 billion US investment strengthens the core Behring business and secures long term immunoglobulin supply. Its planned transformational restructuring is expected to unlock between $500 million and $550 million over three years, turbocharging cash flow. Share buy-backs, a rising dividend and secular demand tailwinds for chronic therapies point to significant upside if management can successfully execute its strategy.

DroneShield Ltd ( ASX: DRO )